The Centre had argued that the five state-owned drug makers had combined revenue of Rs500-550 crore in the past three years, accounting for less than 5% of the sales of Indian pharmaceutical industry. These enterprises were no longer of “strategic value” because they did not produce anything that ...
Read more: Calcutta HC strikes down Centre's decision to sell stake in Bengal Chemicals